In the current research, we aimed to investigate whether NaNO3, via sialin, attenuates metabolic disorders, especially MASLD and T2DM, by modulating the inflammatory responses of MoMFs to balance immune homeostasis. Here, SLC17A5 is linked to metabolic dysfunction-associated steatotic liver disease.